Här är en kvalitativ analys av ett företag som jag gillar… och som jag äger. 
We reiterate our Accumulate recommendation and EUR 9.00 target price for Scanfil. We have included the SRX acquisition announced last week in our forecasts, but the forecast changes were diluted by market-related reasons. At the group level, the near-term changes to the estimates were relatively minor. Scanfil is still very moderately priced in our view (2025e P/E 11x). We believe the stock offers a good expected return at current valuation levels, especially for medium-term investors, despite the clear near-term market risks.